Is AICAR legal  

AMPK was officially named for the first time in 1988 in a paper published in the European Journal of Biochemistry.  Because of AMPK’s role in cell function, the study of AMPK agonists is extremely important.  

However, developing a drug that can directly activate AMPK and have a therapeutic effect has been a challenge.  The development of AMPK direct agonists initially focused on finding compounds that mimic nucleoside dependent activation, although the nature of nucleotide binding sites on AMPK was unknown at the time.  

Until many years later that 5-imidazole-4-carboxyamide ribonucleotide (also known as ZMP) was discovered as a direct agonist of AMPK, a monophosphate derivative of the cellular permeable precursor AICAR.  At fact,AICAR was first used in 1980 as a way to keep blood flowing to the heart during surgery.  

With the emergence of AMPK agonists, researchers and scholars began a frenzy of research on AMPK. Until 2019, two scientists from Maxster University in Canada and Imperial College London in the UK published an in-depth review article in Nature Reviews Drug Discovery.  The great potential of targeted AMPK treatment in a variety of disease areas, including metabolic diseases, cancer, neuromuscular diseases, chronic kidney disease, pain and aging, was evaluated in detail. 

Cancer, which accounts for a quarter of all human deaths, has always been the focus of scientific research.  Aging is something that is relevant to every individual human being;  The basis of living organisms is cells, and AMPK plays an extremely important role in living organisms by acting directly on cells. 

Activation of AMPK leads to phosphorylation of more than 100 proteins in different metabolic pathways, and phosphorylation of a large number of key proteins affects lipid, cholesterol, carbohydrate, and amino acid metabolism, as well as mitochondrial function, autophagy, and cell growth.  

AMPK indirectly affects the utilization of carbohydrates by regulating fatty acid metabolism, and directly regulates the pathways that control carbohydrate metabolism through various mechanisms, reducing calorie intake and increasing energy expenditure are both regulated by AMPK.  

AMPK affects muscle function in many ways, and the use of AMPK activators can cause the same physical changes in bodybuilding, potentially improving performance for bodybuilder.  

Currently, AICAR can be synthesized in the laboratory and is being evaluated in clinical studies and human trials. AICAR is safe at the dosage used by researchers, but the effect of AICAR activation of AMPK is very complex and involves too many different metabolic pathways in the body.  The specific side effects of AICAR activation of AMPK are still being studied.  What is known is that over-activating AMPK, or activating it in the wrong tissue, can lead to changes including neurodegeneration or prevent cell division.  

AICAR is an experimental compound that could be used clinically to treat metabolic disorders, but has not been approved for use in humans.  

However, AICAR, as an AMP analogue, has been widely used in clinical studies to activate AMPK, and its effects on cells have attracted people’s attention. More and more people are using it to control weight and bodybuilding.  

We are the raw material manufacturer of AICAR and provide AICAR powder with purity higher than 99%. HPLC,MS and HNMR are used to ensure the quality of each batch of products. None of the customers who purchased products from us have any quality problems at present.  

If you are interested in AICAR Powder, you can contact us for more information.